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1 The concentration of 5-hydroxytryptamine (5-HT) in rat platelet-free plasma increased significantly
30 min after a single i.p. injection (10 mg kg-') of each of six inhibitors of the high-affinity 5-HT uptake
(fluvoxamine, fluoxetine, alaproclate, paroxetine, sertraline and clomipramine). The increases ranged
from 226% to 776% of control values. In contrast, imipramine, desipramine and femoxetine had no
significant effect. The increase elicited by paroxetine was dependent on the dose (1, 5 and 10 mg kg-')
and returned to control values after 4 h. That observed after clomipramine was also transient and
paralleled the plasma concentration of the drug (Spearman-rank correlation r = 0.43).
2 In vivo, the rat pulmonary vascular endothelium removed trace amounts (8.8 nmol in a bolus) of
intravenously injected ['4C]-5-HT. Paroxetine pretreatment (10 mg kg-', 30 min before-hand) reduced
this uptake by 73%.
3 Repeated fluoxetine treatments reduced rat whole blood 5-HT concentration (ca. - 60% after daily
2 x 5 mg kg-', i.p. during 14 days). However, plasma (extracellular) 5-HT was not increased.
4 Various repeated treatments with clomipramine (i.p. injections or osmotic minipumps, up to
30 mg kg-' day-'), failed to decrease rat whole blood 5-HT concentrations. Platelet-free plasma 5-HT
was also unchanged, even after treatments yielding plasma clomipramine levels 2.7 times higher than
those that increased it acutely.
5 These results indicate that the extracellular pool of 5-HT in rat blood (measured in the platelet-free
plasma) is physiologically under the control of high-affinity 5-HT uptake systems. The sustained 5-HT
uptake inhibition does not result in an increase of 5-HT in platelet-free plasma, suggesting that
adaptative mechanisms are triggered. The distinct long-term effects of the two antidepressants clomi-
pramine and fluoxetine on rat whole blood 5-HT suggest a differential in vivo action on the rat 5-HT
uptake.
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Introduction
Central nervous system (CNS) 5-hydroxytryptaminergic neur-
otransmission is of key importance for the clinical effects of
antidepressant drugs (Shopsin et al., 1975; 1976; Delgado et
al., 1990). However, the study of the actions of antidepres-
sants in human CNS is complicated by the fact that only
indirect measures of neurotransmitter function can be used,
which are scarce and difficult to interpret (see Murphy et al.,
1990 for review). Platelets have been used extensively because
of their similarities with 5-hydroxytryptamine (5-HT) nerve
terminals, particularly for the presence of amine storage
granules and a high-affinity transporter for 5-HT (Stahl,
1985). However, platelets lack noticeable synthesis and meta-
bolism of 5-HT, so that they provide only a restrictive view
of the 5-HT system. In recent years, several laboratories have
studied the effects of certain pathologies and pharmacological
treatments on the extracellular 5-HT in the blood of
psychiatric patients (Sarrias et al., 1987; Cook et al., 1988;
Artigas et al., 1989; Rupprecht et al., 1989; Celada et al.,
1990). This variable is sensitive to rapid and sustained
changes of 5-HT synthesis and metabolism (Ortiz et al., 1988;
Celada et al., 1990) and therefore may overcome some of the
limitations of the measure of 5-HT in platelets. Extracellular
5-HT concentrations in venous human blood (measured in
platelet-free plasma) account for less than 1% of total blood
5-HT, the rest being stored in platelets (Ortiz et al., 1988).
The low concentration (5-15 nM) of extracellular 5-HT is a
consequence of potent mechanisms removing 5-HT from the
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bloodstream (high-affinity uptake into platelets and endo-
thelial cells and monoamine oxidase (MAO) deamination)
after its release from enterochromaffin cells (Verbeuren,
1989). In different areas of rat brain, extracellular and tissue
5-HT maintain a similar proportion due to 5-HT reuptake
(Adell et al., 1991). Extracellular 5-HT in rat brain increases
several fold after treatment with different uptake inhibitors
(Kalkn et al., 1988; Auerbach et al., 1989; Carboni & Di
Chiara, 1989; Adell & Artigas, 1991) confirming in vivo that
uptake is a basic mechanism of the control of extracellular-
and therefore, receptor-available-5-HT. Since the 5-HT up-
take systems also control the equilibrium between extra- and
intracellular 5-HT in blood, the effects of 5-HT uptake
inhibitors on extracellular 5-HT can also be studied in vivo
outside the CNS. The aim of the present work was to study
the effects of several high-affinity 5-HT uptake inhibitors, the
working hypothesis being that they should increase the extra-
cellular concentration of 5-HT in rat blood (measured in
platelet-free plasma). Also, platelet 5-HT concentration
should decrease only after sustained uptake inhibition. The
hypothesis was confirmed after acute treatment, repeated
treatment yielding unexpected results that are discussed.
Methods
Animal treatment
Male Wistar rats of 250-300 g (Iffa-Credo, Lyon, France)
were kept in a controlled environment (220C) with a light/
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dark periodicity of 12 h, at least for one week before the
experiments. They were housed four per cage with water and
food ad libitum.
Acute administration of uptake inhibitors was carried out
i.p. to groups of 7-12 animals randomly chosen. In each
experiment, a control group was injected with saline and
processed along with the treated groups. Usually the acute
effects of 2 or 3 different treatments were examined during
the same experiment.
For the repeated administration of drugs, Alzet mini-
osmotic pumps (Model 2002, Palo Alto, U.S.A.) were
implanted subcutaneously under light ether anaesthesia. Clo-
mipramine was dissolved in 2% Tween and fluoxetine in
50% dimethyl sulphoxide (DMSO) due to the low volume of
mini-pumps. Control rats were implanted with pumps filled
with the corresponding vehicles. Interindividual variance of
weights was corrected by the method of Greenshaw (1986).
Since the animals increased their weights during the treat-
ment (two weeks), the drug doses reported correspond to
those expected on the 7th day. Animals with implanted
minipumps were housed individually to avoid reciprocal
gnawing of sutures observed after some treatments.
Blood sampling
Blood sampling was routinely carried out between 16 h
00 min and 19 h 00 min. Under pentobarbitone anaesthesia
(70 mg kg-', i.p. Sagatal, RMB, U.K.), the blood was drawn
from the carotid artery through a polythene cannula (Portex,
U.K.) cut bevelled (0.58 mm i.d., 4-15 cm long) into three
Eppendorf tubes. The cannula and the sampling tubes con-
tained K2-EDTA calculated to give a final concentration of
0.5-1% (w/v) EDTA in blood. The use of this method of
blood sampling is due to the necessity of avoiding 5-HT
release from platelets that would occur after more traumatic
methods. The blood of the first tube (0.8 ml) was used for the
determination of whole blood 5-HT content. The second and
third tubes (1.5 ml of blood each) were centrifuged (12,000 g,
5 min. 220C). The resulting supernatant (platelet-free plasma)
was carefully removed and frozen at - 80°C until analysed.
Extracellular 5-HT and 5-hydroxyindoleacetic acid (5-HIAA)
concentrations were determined in platelet-free plasma of the
second tube. With this method, mean values of 5-HT in the
platelet-free plasma of rats are usually in the low nm range
(Ortiz et al., 1991a,b).
High performance liquid chromatography analysis
The 5-HT concentration in platelet-free plasma was deter-
mined by high performance liquid chromatography (h.p.l.c.)
coupled to electrochemical detection after a butanol/heptane/
HCl extraction procedure (Artigas et al., 1985). Whole blood
5-HT analysis was carried out as described in Ortiz et al.
(1988). In both cases, bufotenine (N,N-dimethylserotonin)
was used as internal standard. Plasma 5-HIAA determination
was carried out as described for human blood (Martinez et
al., 1983). Minor modifications of these methods were intro-
duced in order to use smaller volumes of sample. Plasma
total tryptophan (TRP) was also analysed by h.p.l.c. and
fluorescence detection (280/340 nm). Plasma clomipramine
(CIM) levels were monitored by the method of Langerstrdm
et al. (1983), that involves a diethyl ether/HCl extraction
from plasma at pH 3.5 and h.p.l.c. - u.v. determination with
desipramine as internal standard.
Effect ofparoxetine on the endothelial ['4C]-S-HT
uptake
The pulmonary removal of ["4C]-5-HT from blood was mea-
sured in vivo by a modification of the method described by
Catravas & Gillis (1980). Rats (350-450 g) were pretreated
with saline or paroxetine (10mgkg-', i.p., 30min before,
n =4 rats/group) and anaesthetized with pentobarbitone
(70 mg kg-1, i.p.). Then, a bolus of 500 nCi of ['4C]-5-HT
(8.8 nmol) (Amersham) was injected into the jugular vein.
Blood was being collected simultaneously at 1-s intervals
through a cannula placed in the carotid artery into tubes
containing K2-EDTA (120-150 gl of blood/tube). Blood
(50gl) from each tube was processed as for whole blood
5-HT determination and then subjected to liquid scintillation
counting instead of h.p.l.c. '4C d.p.m. ml-' of blood was
calculated in each 1 s sample, by use of a ['4C]-5-HT standard
addition curve that was processed in parallel. To another set
of rats (n = 3), 1 mg indocyanine green (cardiogreen) was
injected as reference for the calculation of ["4C]-5-HT uptake.
This compound does not leave the cirulation in a single
passage through the lungs. Its concentration was measured
by optic densitometry at 675 nm in plasma, in parallel to a
standard addition curve of colorant. The area under the
curve (d.p.m. or optic density of colorant) was used to
calculate ['4C]-5-HT uptake with the formula:
% 5-HT uptake= [1 (d.p.m. mlP')/d.p.m. injected ] 100
(mg ml-')/mg injected
'4C uptake represents the percentage of the total amine
injected that was removed by endothelial 5-HT uptake during
a single passage through the lungs (Catravas & Gillis, 1980).
Drugs
The following drugs were kindly provided: clomipramine,
imipramine and desipramine (Ciba-Geigy), paroxetine (Bee-
cham), fluoxetine (Eli, Lilly & Co.), fluvoxamine (Duphar),
sertraline (Pfizer), alaproclate (Astra) and femoxetine (Fer-
rosan). The doses used correspond to the free compound.
H.p.l.c. standards were from Sigma and the rest of the
products were of the highest purity commercially available.
Statistics
The statistical significance of the changes induced by uptake
inhibitors was assessed by one-way ANOVA followed by
Student-Neuman-Keuls comparisons between the drug and
saline groups. The effects of treatments on plasma 5-HT were
evaluated by use of non-parametric statistics (Kruskal-Wallis
test followed by Mann-Whitney U-test) because of the
skewed statistical distribution of the variable in control rats
(Ortiz et al., 1991a). Accordingly, plasma 5-HT is represented
in the figures by its median. Statistical significance was set at
P <20.05.
Results
Acute effects
Increase ofplasma S-HT by selective high-affinity S-HT uptake
inhibitors A single dose of the following drugs (10 mg kg-',
i.p., 30 min before blood sampling) increased rat plasma
5-HT (P< 0.05) vs saline-treated rats: fluvoxamine, fluox-
etine, alaproclate, paroxetine, sertraline and clomipramine
(Table 1). In contrast, the increases induced by imipramine,
desipramine and femoxetine did not reach statistical
significance. Whole blood 5-HT (>99% in platelets; Ortiz et
al., 1988), was not modified in a consistent manner although
slight decreases were observed after fluvoxamine, fluoxetine
and imipramine.
Plasma 5-HIAA increased significantly after the acute
administration of paroxetine ( + 110%), fluoxetine ( + 90%)
and sertraline ( + 49%) (P <0.05). More moderate changes
were elicited by alaproclate ( + 32%) and imipramine
(- 16%). Plasma tryptophan was unchanged by these treat-
ments.
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Table 1 Increase of plasma 5-hydroxytryptamine (5-HT)
produced by acute 5-HT uptake inhibitors
Drug
Fluvoxamine
Fluoxetine
Alaproclate
Paroxetine
Sertraline
Desipramine
Clomipramine
Femoxetine
Imipramine
Controls
median
interquartile r;
(n)
7.6
3.9-13.2 (10)
7.6
3.9-13.2 (10)
8.1
5.4-28.8 (10)
14.1
7.7-24.8 (10)
8.1
5.4-28.8 (10)
8.1
5.4-28.8 (10)
6.8
3.7-11.8 (9)
8.1
5.4-28.8 (10)
7.6
3.9-13.2 (10)
Treated
median
*ange interquartile range % of
(n)
59
19.4-104 (11)
39.6
22-63 (11)
37.5
18.8-61.9 (10)
50.6
38.6-77.2 (11)
27
15.6-86 (11)
20.7
7.1-139 (12)
15.5
9.5-43 (8)
15.1
10.5-131 (11)
12.4
7.6-116 (11)
controls
776%*
520%*
465%*
358%*
335%*
257%
226%*
187%
185%
Plasma 5-HT is given in nmol 1-'. *P <0.05 versus
respective saline-treated animals, Kruskal-Wallis and
Mann-Whitney tests. The data shown correspond to four
different experiments in which median control values were
not different (Kruskal-Wallis test).
Drug-effect relationships Different doses of paroxetine were
administered to randomized groups of animals (0, 1, 5 or
10 mg kg-', i.p., 30 min before), eliciting dose-dependent in-
creases in plasma 5-HT and 5-HIAA as shown in Figure 1.
Whole blood 5-HT was not modified by such treatments.
The kinetics of the increase of extracellular 5-HT were
studied after the administration of clomipramine and parox-
etine. Groups of animals treated with a single dose of either
drug (10 mg kg-1, i.p.) were killed at different times post-
administration: 15 min (only for paroxetine), 30 min, 1 h, 2 h
and 4 h. With both drugs, plasma 5-HT rose maximaly at
30 min, returning to control values after 4 h. The increase of
plasma 5-HT elicited by clomipramine (CIM) clearly paral-
leled the plasma concentration of the drug (Figure 2). In
addition, the individual values of 5-HT and CIM in plasma
correlated significantly (Spearman rank correlation r = 0.43,
n=41, P<0.05).
Effects of paroxetine pretreatment on the endothelial ['4C]-5-
HT uptake The pretreatment with paroxetine (1Omg kg-',
i.p., 30 min before) elevated the amount of ['4C]-5-HT left in
blood after a single passage of the lungs. This is shown by
the difference in the area under the curve represented in
Figure 3. Saline-pretreated rats removed 47 ± 22% of the
[14C]-5-HT bolus, while the paroxetine group removed
13 ± 27% (means ± s.d. of n = 4 rats per group, P<0.05
Mann-Whitney test). Thus, paroxetine elicited a 73% reduc-
tion in the endothelial 5-HT removal.
Effects of sustained uptake inhibition
Effects of repeated clomipramine In a first experiment, re-
peated intraperitoneal administrations of CIM (15 mg kg-'
daily for 2, 4, 7, 14 or 21 days, killing 24 h after the last
injection) did not modify the concentrations of total tryp-
tophan, 5-HT and 5-HIAA in plasma nor 5-HT in whole
blood (data not shown). The lack of effect on whole blood
5-HT was surprising, since lower doses decrease by more
than 90% platelet 5-HT in depressive patients (Sarrias et al.,
1987). Given the short half-life of CIM in rat plasma after
repeated administration (Friedman & Cooper, 1983), it is
0
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Figure 1 Dose-related increase of extracellular 5-hydroxytryptamine
(5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) in plasma elicited
by the selective high-affinity 5-HT uptake inhibitor paroxetine. Saline
(open column) or paroxetine I mg kg-' (solid column), 5 mg kg-'
(hatched column) or 10 mg kg-' (cross-hatched column) were
administered i.p. 30min before blood sampling. Values are repre-
sented as medians (plasma 5-HT) or means ± s.e.mean (vertical lines)
of 10 to 12 rats per group. Control values were: plasma 5-HT,
14.1 nM; whole blood (WB) 5-HT, 8.23 Itm; plasma 5-HIAA, 81 nM.
P< 0.05 versus saline-treated animals, Kruskal-Wallis and Mann-
Whitney tests (plasma 5-HT) or one-way ANOVA and Student-
Newman-Keuls (plasma 5-HIAA).
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Figure 2 Time- and drug level-dependent increase of extracellular
5-hydroxytryptamine (5-HT) in plasma elicited by i.p. administration
of 10mg kg-' of the high-affinity 5-HT uptake inhibitor clomipra-
mine (CIM). Columns represent plasma 5-HT medians and (0) are
means ± s.e.mean (vertical lines) of plasma CIM (7-10 rats per
group). P<0.05 versus saline-treated animals, Kruskal-Wallis and
Mann-Whitney tests. Plasma 5-HT and CIM levels correlated
significantly (Spearman-rank correlation r = 0.43, n = 41, P<0.05).
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Figure 3 Effect of paroxetine pretreatment on the in vivo pulmonary
vascular endothelial removal of ['4C]-5-hydroxytryptamine (['4C]-5-
HT), 30 min before the rats were pretreated with saline (0) or
paroxetine 10mg kg-' (0). At time zero, 8.8 nmol of radiolabelled
5-HT was injected into the jugular vein while blood was being
sampled each second through the carotid artery. The ordinate scale
(d.p.m.) represents the radiolabelled 5-HT that escaped the endo-
thelial removal of the amine. The data are means of four different
experiments per group; s.e.mean shown by vertical lines. (P<0.05
two-tailed Student's t test.
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Figure 4 Dose-related effects of chronic clomipramine administra-
tion by osmotic mini-pumps. Treatments used were vehicle (open
column), clomipramine 15 mg kg-' day-' for 7 days (solid column),
15mg kg'- day- ' for 14 days (hatched column) or 30mg kg-' day-'
for 14 days (cross-hatched column). No change was observed in
plasma and whole blood 5-hydroxytryptamine (5-HT) even at the
highest drug levels. Values are expressed as medians (plasma 5-HT)
or means ± s.e.mean (vertical lines) of 7 to 19 rats per group.
P<0.05 versus controls, one-way ANOVA and Student-Newman-
Keuls comparisons. Control group pools data from two experiments
with slightly different values: plasma tryptophan (TRP), 82 gM and
74gM; plasma 5-HT, 13.5 nm and 12.2 nM; whole blood (WB) 5-HT,
7.2 jM and 8.6 tM (P <0.05 two-tailed Student's t test) and plasma
5-hydroxyindoleacetic acid (5-HIAA), 164 nm and 104 nM (P<0.05
two-tailed Student's t test). The statistical significances did not vary
when each control group was considered alone.
likely that steady-state levels were not achieved. Therefore,
we used a more sustained administration, by means of sub-
cutaneously implanted mini-osmotic pumps. The treatments
used were: 15mg kg-' daily for 7 or 14 days, and 30mg kg-'
daily for 14 days, with no wash-out period at the end of the
administration. Although the drug plasma levels obtained
were within the therapeutic concentrations found in
depressed patients (mean values: 54, 164 and 401 nM CIM in
plasma, respectively), plasma and whole blood 5-HT were
not modified. Plasma total tryptophan decreased moderately
both in the l5mgkg-' day-', 14 days (- 19%) and in the
30mg kg-' day-', groups (-23%, P<0.05). Plasma 5-
HIAA concentration decreased only in the 30 mg kg-' day-'
group (- 46%, P<0.05) (Figure 4). Regression analysis
showed a positive correlation between plasma TRP and 5-
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Figure 5 Dose-related effects of chronic fluoxetine administration.
Treatments used were vehicle (open column), fluoxetine 5 mg kg-'
day-' for 14 days using mini-osmotic pumps, no washout (solid
column) or 2 x 5 mg kg-' day-' i.p. for 14 days, 48 h wash-out
(cross-hatched column). *P<0.05 versus controls, one-way ANOVA
and Student-Newman-Keuls. Respective mean control values were
8.6 gM and 9.4 gM (not significantly different, two-tailed Student's t
test).
HIAA (Pearson's correlation r = 0.52, P<0.05, n = 34), and
a dependence of both variables on CIM levels (r = - 0.47
and - 0.42 respectively, P <0.05). Multiple regression
analysis showed that the correlation between 5-HIAA and
CIM was due to that between tryptophan and CIM. Body
weight gain during the treatments was lower in the clomip-
ramine groups than in controls (data not shown).
Effects of repeated fluoxetine Repeated administration of
fluoxetine was carried out in two experiments, using either
mini-osmotic pumps or i.p. injections. Subcutaneously im-
planted pumps (5 mg fluoxetine kg-' day-' for 14 days, no
wash-out) decreased whole blood 5-HT (- 36% vs. vehicle-
treated rats, P<0.05 two-tailed Student's t test) (Figure 5).
Plasma 5-HT was unaltered (median control values: 12.2 nM;
fluoxetine: 11.6 nM). Neither plasma 5-HIAA nor plasma
total tryptophan concentration were significantly changed.
Intraperitoneal injections (5 mg kg-', twice daily for 14 days,
followed by 48 h wash-out) decreased whole blood 5-HT
(- 59% vs. saline-treated controls, P <0.05 Student's t test).
Plasma 5-HIAA was not significantly changed by fluox-
etine. Control values were significantly different between both
experiments: Lower values were observed in the rats injected
i.p. daily (80.4 ± 16.8 nM) than in those with an implanted
pump (104.1 ± 13.7 nM; means ± s.d., P<0.05 two-tailed
Student's t test). This difference may result from the stress of
handling non-habituated animals (pump group) at the time
of the experiment. This can moderately increase plasma 5-
HIAA probably through activation of 5-hydroxy-
tryptaminergic function (unpublished observations).
Discussion
In recent years it has been shown that an extracellular pool
of 5-HT occurs in low nM concentrations in human blood, in
addition to the well-known platelet pool (Artigas et al., 1985;
Anderson et al., 1987; Ortiz et al., 1988). When appropriate
experimental conditions are used, the 5-HT found in platelet-
free plasma is a good estimate of the extracellular pool.
Independent changes of the extracellular and platelet pools in
man have been reported in pathological conditions and after
some pharmacological treatments known to affect the 5-HT
system (Sarrias et al., 1987; Cook et al., 1989; Artigas et al.,
1989). In rats, little is known about this extracellular pool of
5-HT. Results from this laboratory show that its concentra-
tion is similar to that in man, in spite of the fact that rats
contain about ten times more 5-HT than man in the platelet
pool per unit of blood volume (Ortiz et al., 1988; 1991a,b).
The present results indicate that in the rat, the plasma pool
of 5-HT (but not the platelet one) is markedly increased after
short-term uptake inhibition. This is consistent with the
occurrence of high-affinity 5-HT uptake present in the
platelets and vascular endothelial cells and perhaps in entero-
chromaffin cells and their physiological role in removing
extracellular 5-HT (Verbeuren, 1989). The increase of plasma
5-HT was dependent on the dose of the uptake inhibitor (e.g.
paroxetine). Also, it followed the evolution of drug plasma
levels (clomipramine), which suggests that the turnover of
extracellular 5-HT in blood is very rapid.
More marked plasma 5-HT increases were obtained with
the new antidepressants which are selective 5-HT uptake
inhibitors rather than with the tricyclic drugs. Also, the three
drugs having the greatest effect (fluvoxamine, fluoxetine and
alaproclate) displayed the same order of potencies as in the
synaptosomal [3H]-5-HT uptake inhibition (Wolf & Kuhn,
1991). This indicates that the increase of plasma 5-HT is
representative of the actual effects of these drugs on the 5-HT
transporter in vivo. In addition, unlike in vitro procedures(sometimes performed far from physiological conditions,
such as the binding of [3H]-imipramine to platelets at 0C),
the increase of plasma 5-HT takes into account other factors
that may influence the interaction of the drug with its phar-
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macological target (bioavailablity, metabolism and excretion,
interaction with other mechanisms of control, etc).
Besides platelets, endothelial cells have a 5-HT transporter
sensitive to imipramine (Catravas & Gillis, 1980; Bosin &
Lahr, 1981; Robinson-White et al., 1981; Lee & Fanburg,
1986). To examine the contribution of endothelial uptake to
the increases of extracellular 5-HT in rats, we tested in vivo
the effects of a single dose of paroxetine. Saline-treated
animals removed almost 50% of the injected ['4C]-5-HT
(8.8 nmol) in a single passage through the lungs. Paroxetine
elicited an important reduction (- 73%) of the removal of
this physiological amount of 5-HT (as ['4C]-5-HT) by the
lungs, in parallel with a marked increase of plasma 5-HT
(Table 1). These figures support the view that the endothelial
uptake is a very important factor for the control of extracel-
lular 5-HT in blood in vivo, confirming earlier data obtained
with rat isolated lungs (Steinberg & Das, 1980). Also, the
present results prove that the rat endothelial removal of
5-HT is sensitive to specific 5-HT uptake inhibitors, such as
paroxetine.
Some of the specific 5-HT uptake inhibitors acutely in-
creased plasma 5-HIAA concentration. This is formed by
MAO-A in the liver and, after high-affinity 5-HT uptake, in
the vascular endothelium (Verbeuren, 1989). The effects on
the plasma 5-HIAA concentration probably derive from a
major availability of extracellular 5-HT to the liver, since
5-HT can enter the hepatocytes from portal blood without
specific uptake (Wiersma & Roth, 1980). However, the lack
of a significant effect of fluvoxamine, which increased plasma
5-HT maximally, suggests that other factors may be
differentially affected by the several drugs used (e.g. effects on
the release of 5-HIAA by enterochromaffin cells, renal
clearance, etc).
The next step was to examine the effects of repeated
administration of 5-HT uptake inhibitors. Clomipramine and
fluoxetine were chosen for their wide use in psychiatric prac-
tice for the treatment of depression, obsessive-compulsive
and panic disorders. Two different repeated treatments with
fluoxetine decreased whole blood 5-HT, indicating that the
platelet high-affinity 5-HT uptake mechanism was effectively
inhibited. Despite the 48 h wash-out used in the i.p. treat-
ment, platelet 5-HT was markedly reduced. The slow
metabolism of fluoxetine (Caccia et al., 1990) probably
accounts for this. However, plasma 5-HT was not increased
as in the acute effects. This indicates the presence of adaptive
mechanisms leading to a decrease of the circulating extracel-
lular 5-HT. Repeated fluoxetine treatment does not increase
extracellular 5-HT in the frontal cortex of rats (Sarkissian et
al., 1990), perhaps due to a reduction of brain 5-HT turnover
(Fuller et al., 1974). In the periphery, a decreased synthesis
by or release from enterochromaffin cells could explain the
reduction of 5-HT in the bloodstream after repeated fluox-
etine treatment.
Long-term treatment with clomipramine failed to decrease
rat whole blood 5-HT, despite achieving a stable plasma
CIM concentration (up to 400 nM). In depressive patients, a
two-week treatment with CIM (mean plasma levels: 205 nM)
elicited a 90% reduction of platelet 5-HT (Sarrias et al.,
1987). Clomipramine, unlike other tricyclic antidepressants,
has very potent and long-lasting effects on the [3H]-imi-
pramine binding and [3H]-5-HT uptake in human platelets
(Mellerup & Plenge, 1986; Poirier et al., 1984; 1987). How-
ever, such long-lasting effects may not occur in rats. Acute
CIM increased plasma 5-HT, but this change paralleled
closely CIM levels in plasma. Therefore, interspecies
differences in the interaction of CIM with the platelet 5-HT
uptake transporter in vivo seem likely. Errebo et al. (1991)
have studied in detail the drug-carrier interactions in synap-
tosomal preparations in vitro, revealing drug and species
differences of the dissociation times of [3H]-imipramine, [3H]-
paroxetine and [3H]-citalopram from the 5-HT transporter.
However, the relationship of these differences to the present
results is uncertain. In addition, the CIM plasma levels
obtained after long-term treatment were higher (up to 2.7
times) than those increasing plasma 5-HT acutely, but no
change of this pool was observed. Thus, the triggering of
adaptive mechanisms of peripheral 5-HT physiology is likely,
as for fluoxetine.
In summary, the present work shows that plasma 5-HT is
highly dependent on transient, but not sustained, inhibition
of the high-affinity 5-HT uptake. Also, the marked
differences in the effects elicited by fluoxetine and clomip-
ramine suggest that their in vivo interaction with the rat
platelet 5-HT transporter may be clearly distinct. Therefore,
caution should be taken in extrapolating to man the effects of
certain uptake inhibitors on the rat high-affinity 5-HT
uptake.
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